These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22552811)

  • 21. 17q12-21 - the pursuit of targeted therapy in breast cancer.
    Glynn RW; Miller N; Kerin MJ
    Cancer Treat Rev; 2010 May; 36(3):224-9. PubMed ID: 20100636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
    Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
    Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
    Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
    Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2008; 49(4):469-78. PubMed ID: 19050794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
    Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
    Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
    Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
    Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
    Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
    Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
    Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
    Nadler Y; González AM; Camp RL; Rimm DL; Kluger HM; Kluger Y
    Ann Oncol; 2010 Mar; 21(3):466-473. PubMed ID: 19717535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma.
    Bivin WW; Yergiyev O; Bunker ML; Silverman JF; Krishnamurti U
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):553-558. PubMed ID: 26945445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines.
    Lim RC; Price JT; Wilce JA
    Breast Cancer Res Treat; 2014 Feb; 143(3):593-603. PubMed ID: 24464577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.
    Tang Y; Yang S; Wang M; Liu D; Liu Y; Zhang Y; Zhang Q
    Int J Mol Med; 2019 Jun; 43(6):2352-2360. PubMed ID: 31017268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bcl-2 as a prognostic factor in different molecular genetic subtypes of breast cancer].
    Pavlenko IA; Povilaĭtite PE; Gorelik MZ; Petrov AV
    Arkh Patol; 2012; 74(5):36-40. PubMed ID: 23342658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.